Figure 3.

Reverse transcription-quantitative polymerase chain reaction for validation of the gene expression profiles. Subsequent to extracting total RNA from the tumors, complementary DNA was created using a First Strand cDNA Synthesis kit. Gene expression assays were then used to validate the differential mRNA expression levels of various identified genes, including (A) MMP9 and (B) SERPINE1 in the recurrent and non-recurrent triple-negative breast cancer samples. MMP9, matrix metalloproteinase 9.